ADiTx Therapeutics Total Assets 2011-2026 | ADTX

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets ADiTx Therapeutics

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
32.1 M	44.6 M	10.7 M	16.7 M	13.1 M	124 K	116 K	25 K	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
44.6 M	25 K	14.7 M

Quarterly Total Assets ADiTx Therapeutics

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
32.7 M	31.2 M	32.1 M	29.8 M	28.4 M	28 M	44.6 M	8.23 M	7.29 M	7.63 M	10.7 M	19.2 M	10.7 M	11.8 M	16.7 M	19.6 M	15.9 M	18 M	13.1 M	13.1 M	13.1 M	13.1 M	124 K	124 K	124 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
44.6 M	124 K	17 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
Precigen PGEN	156 M	$ 3.1	-0.96 %	$ 758 M	USA
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
ARCA biopharma ABIO	396 M	-	1052.0 %	$ 415 M	USA
Aeterna Zentaris AEZS	35.1 M	-	5.93 %	$ 314 M	Canada
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	151 M	-	2.54 %	$ 160 B	France
Albireo Pharma ALBO	302 M	-	-0.23 %	$ 916 M	USA
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Ascendis Pharma A/S ASND	1.3 B	$ 220.9	2.49 %	$ 5 B	Danmark
Aileron Therapeutics ALRN	62.2 M	-	10.36 %	$ 9.8 M	USA
Midatech Pharma plc MTP	14.8 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
Amphastar Pharmaceuticals AMPH	1.63 B	$ 19.57	1.77 %	$ 915 M	USA
AgeX Therapeutics AGE	6.95 M	-	-10.17 %	$ 12.2 K	USA
Aptinyx APTX	66.7 M	-	-39.0 %	$ 4.57 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	72 M	-	4.01 %	$ 150 M	Canada
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Adverum Biotechnologies ADVM	180 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	11.6 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Avenue Therapeutics ATXI	2.67 M	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	783 M	$ 1.33	0.76 %	$ 339 M	Britain
Atreca BCEL	155 M	-	-11.76 %	$ 5.79 M	USA
BeiGene, Ltd. BGNE	8.19 B	-	0.49 %	$ 251 B	Cayman-islands
bluebird bio BLUE	619 M	-	-	$ 546 M	USA
ProQR Therapeutics N.V. PRQR	113 M	$ 1.58	6.04 %	$ 99.5 M	Niderland
BioDelivery Sciences International BDSI	325 M	-	-4.8 %	$ 255 M	USA
Cara Therapeutics CARA	126 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	426 M	-	-	$ 3.74 B	USA
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
Avid Bioservices CDMO	337 M	-	-	$ 789 M	USA
CureVac N.V. CVAC	1.16 B	-	-	$ 867 M	Germany
Bellerophon Therapeutics BLPH	7.94 M	-	-74.18 %	$ 955 K	USA
Corbus Pharmaceuticals Holdings CRBP	168 M	$ 8.31	1.59 %	$ 111 M	USA
CRISPR Therapeutics AG CRSP	2.27 B	$ 47.09	1.42 %	$ 4.23 B	Schweiz
Arbutus Biopharma Corporation ABUS	94.6 M	$ 4.53	5.1 %	$ 868 M	Canada
AIkido Pharma AIKI	47.1 M	-	1.93 %	$ 17.4 M	USA
Allakos ALLK	244 M	-	-	$ 28.6 M	USA
Brickell Biotech BBI	11.6 M	-	-5.38 %	$ 6.06 M	USA
CytomX Therapeutics CTMX	152 M	$ 4.22	-0.47 %	$ 582 M	USA
Allena Pharmaceuticals ALNA	34.8 M	-	3.16 %	$ 1.9 M	USA
Calithera Biosciences CALA	64.8 M	-	-10.95 %	$ 876 K	USA
Alpine Immune Sciences ALPN	287 M	-	-	$ 2.17 B	USA
Cyclacel Pharmaceuticals CYCC	4.09 M	-	-5.98 %	$ 34.1 M	USA